Global Vascular Endothelial Growth Factor Inhibitors Market Size, Forecast, and Trend Highlights Over 2025-2037
Vascular Endothelial Growth Factor Inhibitors Market size was valued at USD 12.9 billion in 2024 and is projected to reach USD 33.5 billion by the end of 2037, rising at a CAGR of 8.7% during the forecast period, i.e., 2025 to 2037. In 2025, the industry size of VEGF inhibitors is evaluated at USD 14.3 billion.
The global vascular endothelial growth factor inhibitors market demonstrates vigorous growth driven by the rising applications in oncology and ophthalmology. There is a rapid prevalence of cancer cases, such as lung, colorectal, and breast, coupled with retinal disorders, which exceptionally necessitates the VEGF inhibitors across all nations. According to a clinical study by the National Cancer Institute in 2024, more than 2.2 million cases of cancer were diagnosed in the U.S. Similarly, as per the WHO reports, diabetic retinopathy affected over 140 million people across the world. Therefore, this increasing burden of disorders increases the demand for VEGF inhibitors, thereby propelling market growth.
Furthermore, in 2024, the U.S. Bureau of Labor Statistics reported that the Producer Price Index for biologic pharmaceuticals increased by 4.4%, highlighting the rising production values. Besides, as reported by USITC, the U.S. imports nearly 35.5% of APIs from India and China. For instance, in 2024, Eurostat states that exports of VEGF inhibitor-based drugs reached a substantial value of €5.4 billion. Additionally, business in this sector is driven by expanding research activities; in this context, in 2024, NIH assigned USD 2.9 billion for angiogenesis. Hence, with these factors, the market is anticipated to witness significant growth during the forecast period.
Vascular Endothelial Growth Factor (VEGF) Inhibitors Sector: Growth Drivers and Challenges
Growth Drivers
- Affordable medical interventions: The proven effectiveness of the products from the market makes them preferable for affordable healthcare applications. This further encourages pharmaceutical companies to undergo various clinical trials, deepening the exploration of their potential. In this regard, in 2024, the U.S. FDA approved bevacizumab biosimilars, which are an affordable cancer treatment in the US. This approval is projected to reduce the treatment cost by 35% to 45%. Hence, it lowers hospitalization costs, thereby increasing demand for VEGF inhibitors globally.
- Technological advancements: Another key driver for the vascular endothelial growth factor inhibitors market is the technological advancements in the therapeutic sector. The U.S. FDA states that AI-based algorithms such as Genentech’s Lucentis AutoDose reduced ophthalmic injection frequency by 25.4% in clinical trials. Furthermore, the cell-based VEGF inhibitors, such as Astella’s ASP-8374, demonstrated promising results in resistant cancers in Phase III. In this regard, in 2024, NIH invested USD 3.6 billion in angiogenesis, accelerating the treatment procedures, thereby supporting market upliftment.
Manufacturer Strategies Shaping the VEGF Inhibitors Market
The vascular endothelial growth factor (VEGF) inhibitors market is expanding globally, with strong capability of manufacturers aiming to strengthen their positions in the international market. Key strategies opted by VEGF inhibitor manufacturers include biosimilar innovation, geographic expansion, and the launch of next-generation formulations. Companies such as Roche and Genentech are leveraging FDA fast-track designations for their products, Lucentis and Avastin. Hence, these factors significantly contribute to the market expansion during the forecast timeline.
Revenue Potential for VEGF Inhibitor Manufacturers
|
Company |
Strategy |
Revenue Impact (USD) |
|
Roche/Genentech |
Expanded Avastin oncology use |
+$1.3 billion (2024) |
|
Regeneron |
Eylea 8-week dosing approval |
+$920 million (2023–2025) |
|
Novartis |
Ranibizumab biosimilars in Asia |
+$340 million (2023) |
|
Bayer |
VEGF/cell therapy pipeline |
$530 million R&D investment |
|
Pfizer |
Tiered pricing in Africa |
+$152 million (2024) |
Feasible Expansion Models Shaping the Future VEGF Inhibitors Market
The market is witnessing immense growth, effectively moulding the expansion models such as increasing domestic collaborations, strategic processing, and the launch of exclusive biosimilars across all nations. For instance, in India, Novartis declared a partnership with Apollo Hospitals, which resulted in an increased revenue by 12.3% from 2022 to 2024 for the ophthalmic treatments. Additionally, initiatives such as Bayer’s Africa led to a lowering of the price of ranibizumab by 40.4%, serving around 25,000 affected people annually. Thus, these expansion strategies are anticipated to boost the market growth significantly.
The following is the past years' market revenue growth based on feasibility models:
|
Model |
Region |
Outcome |
Revenue Impact |
|
Hospital Partnerships |
India |
12.3% revenue increase (Novartis) |
+$180.4 million (2022–2024) |
|
Tiered Pricing |
Africa |
40.4% price reduction (Bayer) |
25,000 additional patients |
|
Medicare Expansion |
USA |
9.4% revenue growth (Regeneron) |
+$920 million (2023) |
|
Biosimilar Licensing |
Europe |
30.6% cost savings (Roche) |
€530 million savings (2024) |
Challenges
- Pricing limitations by governing bodies: One of the most significant barriers for the vascular endothelial growth factor (VEGF) inhibitors market to achieve an optimum consumer base is the pricing limitations by the government. In this regard, in 2023, in Europe, countries such as Germany imposed a 26% price control on bevacizumab biosimilars, making it hard for manufacturers to develop such formulations. This eventually resulted in health disparities among patients as the U.S. Medicaid covers only 60.2% of anti-VEGF treatments, thereby hindering market penetration in most countries globally.
Vascular Endothelial Growth Factor (VEGF) Inhibitors Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.7% |
|
Base Year Market Size (2024) |
USD 12.9 billion |
|
Forecast Year Market Size (2037) |
USD 33.5 billion |
|
Regional Scope |
|
Vascular Endothelial Growth Factor (VEGF) Inhibitors Segmentation
Drug Class (Monoclonal Antibodies, Small Molecule Inhibitors, Fusion Proteins)
Based on drug class, the monoclonal antibodies segment is projected to account for the largest share of 48.6% in the vascular endothelial growth factor (VEGF) inhibitors market by the end of 2037. The growth in the segment is subject to the domination of elements such as bevacizumab and ranibizumab with their expanded usage in oncology and ophthalmology applications. In this regard, according to a clinical study by the National Institute of Health, it underscored a 12% annual increase in VEGF-targeting mAbs with improved cancer survival rates. This is the evidence for a wider scope, thereby amplifying the segment’s growth.
Application (Oncology, Ophthalmology)
Based on the application, the oncology segment is projected to account for a lucrative share of 42.7% in the vascular endothelial growth factor inhibitors market during the forecast period. The dominance of the segment is attributable to the increasing instances of cancers across all nations and the usage of VEGF inhibitors as the first-line therapy in such cases. As per the NCI data, VEGF inhibitors are used as primary treatments among 25.4% of non-small cell lung cancer patients. Furthermore, the rising approvals for combo therapies such as PD-1 inhibitors further accelerate the adoption, thereby readily blistering market expansion.
Our in-depth analysis of the global vascular endothelial growth factor inhibitors market includes the following segments:
|
Drug Class |
|
|
Application |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportVascular Endothelial Growth Factor (VEGF) Inhibitors Industry - Regional Synopsis
North America Market Analysis
The North America vascular endothelial growth factor (VEGF) inhibitors market is estimated to account for a share of approximately 38.8% by the end of 2037. The region’s growth is attributed to higher adoption of oncology treatments and Medicare coverage. For instance, in 2024, as reported by CMS, the Medicare expenditure for anti-VEGF drugs reached USD 4.6 billion, whereas NIH contributed an amount of USD 143.2 billion for angiogenesis research. Hence, these factors significantly contribute to the market expansion during the forecast timeline.
The VEGF inhibitors market in Canada is gaining traction due to the expanding medical expenditure in the country. Besides, the VEGF market grows at 7.2% CAGR owing to the increasing instances of cancer in the region. For instance, in 2024, Health Canada reported USD 1.3 billion in federal medical expenditure. Besides, Ontario Public Health reports that it covers nearly 76% of ranibizumab expenses, which benefits more than 50,000 patients in a year. Furthermore, as per CIHI, there has been a rise in AMD cases since 2020 that will increase the demand for VEGF inhibitors in the country, thereby uplifting market growth.
APAC Market Statistics
The vascular endothelial growth factor inhibitors market in the Asia Pacific is unfolding remarkable growth opportunities fueled by a higher number of aging populations, who have a rising burden of severe ocular diseases such as age-related macular degeneration (AMD) and diabetic retinopathy. Both the public and private healthcare initiatives are fostering a favorable business environment in the region with well well-established healthcare sector and insurance schemes. Besides, the widespread support from regulatory frameworks and innovation in drug delivery procedures offers immense potential for the market to expand more.
China is the key leader in the vascular endothelial growth factor (VEGF) inhibitors market in the Asia Pacific region, owing to its highly supportive government initiatives. The country’s focus on offering affordable healthcare solutions, including cancer treatments, improves access to medical care in the region. Moreover, the anti-VEGF drugs have been included in the National Reimbursement Drug List to expand their usage for patients who cannot afford them. Besides, Conbercept has been included in the national basic medical insurance, further enhancing its accessibility, thereby readily achieving market upliftment in China.
Companies Dominating the Vascular Endothelial Growth Factor (VEGF) Inhibitors Landscape
- Regeneron Pharmaceuticals, Inc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Bayer AG
- Amgen Inc.
- Eli Lilly and Co.
- AstraZeneca Plc
- Pfizer Inc.
- AbbVie Inc.
- Biogen Inc.
- Teva Pharmaceutical Industries Ltd.
- Xbrane Biopharma AB
- STADA Arzneimittel AG
- Samsung Bioepis
- Mitsubishi Tanabe Pharma
- Ono Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Co. Ltd.
- LG Chem Ltd.
- Biocon Biologics Ltd.
- Tasly Pharmaceutical Group Co., Ltd.
Companies involved in the vascular endothelial growth factor (VEGF) inhibitors market are gaining immense exposure due to their exclusive product portfolio and ongoing developmental initiatives. For example, companies such as Regeneron Pharmaceuticals, Novartis, and Roche dominate the global market landscape with their core products such as aflibercept (Eylea), ranibizumab (Lucentis), and bevacizumab (Avastin). Furthermore, the firms leverage affordable therapeutics, collaborations, and acquisitions also contribute to a healthy competition among the global players, thereby achieving targeted results in emerging markets.
Here is a list of some prominent players in the market:
Recent Developments
- In May 2024, Genentech created a biodegradable implant that slowly releases ranibizumab (Lucentis) over six months. Phase III trials found it reduces injection frequency by 40% for AMD patients.
- In February 2024, Regeneron Pharmaceuticals received FDA approval for Eylea HD, an 8 mg formulation of aflibercept that allows wet AMD and DME patients to extend treatment from every 8 weeks to every 16 weeks.
- In January 2024, Roche partnered with IBM Watson Health to develop AI-based dosing algorithms for bevacizumab (Avastin) in cancer therapy with 20% fewer side effects and 12% better treatment responses compared to standard dosing.
Author Credits: Radhika Pawar
- Report ID: 2479
- Published Date: May 21, 2025
- Report Format: PDF, PPT
